Back to News
Market Impact: 0.2
Annovis Bio, Inc. Reports Preliminary Cash and Cash Equivalents of approximately $2.8 million
Source: Nasdaq
Company Fundamentals
Annovis Bio preliminarily estimates cash and cash equivalents of approximately $2.8 million as of September 30, 2026. The disclosure provides no further financial figures or outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.10
Ticker Sentiment
ANVS-0.35
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook